Endothelin-1 in Paraventricular Nucleus Modulates Cardiac Sympathetic Afferent Reflex and Sympathetic Activity in Rats

Ai-Dong Chen, Xiao-Qing Xiong, Xian-Bing Gan, Feng Zhang, Ye-Bo Zhou, Xing-Ya Gao, Ying Han

Abstract

Background: Cardiac sympathetic afferent reflex (CSAR) is a positive-feedback, sympathoexcitatory reflex. Paraventricular nucleus (PVN) is an important component of the central neurocircuitry of the CSAR. The present study is designed to determine whether endothelin-1 (ET-1) in the PVN modulates the CSAR and sympathetic activity, and whether superoxide anions are involved in modulating the effects of ET-1 in the PVN in rats.

Methodology/Principal Findings: In anaesthetized Sprague–Dawley rats with cervical vagotomy and sinoaortic denervation, renal sympathetic nerve activity (RSNA) and mean arterial pressure (MAP) were recorded. The CSAR was evaluated by the responses of the RSNA and MAP to epicardial application of capsaicin. Microinjection of ET-1 into the bilateral PVN dose-dependently enhanced the CSAR, increased the baseline RSNA and MAP. The effects of ET-1 were blocked by PVN pretreatment with the ETA receptor antagonist BQ-123. However, BQ-123 alone had no significant effects on the CSAR, the baseline RSNA and MAP. Bilateral PVN pretreatment with either superoxide anion scavenger tempol or polyethylene glycol-superoxide dismutase (PEG-SOD) inhibited the effects of ET-1 on the CSAR, RSNA and MAP. Microinjection of ET-1 into the PVN increased the superoxide anion level in the PVN, which was abolished by PVN pretreatment with BQ-123. Epicardial application of capsaicin increased superoxide anion level in PVN which was further enhanced by PVN pretreatment with ET-1.

Conclusions: Exogenous activation of ETA receptors with ET-1 in the PVN enhances the CSAR, increases RSNA and MAP. Superoxide anions in PVN are involved in the effects of ET-1 in the PVN.

Introduction

Endothelins (ET) are now recognized for their function in central regulation of cardiovascular activity [1,2]. In central nervous system (CNS), ET-1 is produced by vascular endothelial cells, neuron and/or non-neural elements or delivered by way of the cerebrospinal fluid [3]. It has been reported that injection of ET-1 into the cerebral ventricles evokes a pressor response in rats [4], which is mediated by increased sympathetic outflow [5]. Intracerebroventricular administration of the ETA receptor antagonist BQ-123 abolishes the pressor response to ET-1 [6]. Intracerebroventricular injections of ET-1 increases sympathetic nerve activity and blood pressure via ETA receptors but not via ETB receptors in rats [7]. These results suggest that central ET-1 is involved in the modulation of blood pressure and sympathetic output. Earlier studies have shown that the pressor response induced by central ET-1 is due to stimulation of arginine vasopressin (AVP) release [4,8]. However, systemic vasopressin receptor blockade does not inhibit the pressor response induced by central ET-1, and arterial pressure rises equally in normotensive Long Evans rats and in the Brattleboro strain devoid of central AVP [9]. Furthermore, the response of ET-1 in the baroreflex-intact rats is independent from the AVP release [1]. These results suggest that the AVP is not the necessary factor in the pressor response to central ET-1. The mechanisms involved in the pressor and sympathoexcitatory responses to ET-1 in the CNS are still unknown.

It is well established that cardiac sympathetic afferent reflex (CSAR) is a positive-feedback, sympathoexcitatory reflex. The enhanced CSAR partially contributes to the sympathetic excitation in the chronic heart failure (CHF) state [10–12] and hypertension [13,14]. Paraventricular nucleus (PVN) is an important integrative center in the control of the CSAR [15,16]. Abundant ET-1 expression is found in the PVN [17], especially in the parvocellular PVN cells [18]. Autoradiographic visualization of the binding sites for [125I]endothelin shows both ETA receptors and ETB receptor expression in the PVN [3,19,20]. The lesion of
the PVN prevents the intracerebroventricular administration of ET-1-induced increase in arterial pressure [6]. The aminopro- pionic acid receptors in the PVN are involved in mediating the pressor response to ET-1 in subfornical organ (SFO) [21]. These results suggest that PVN plays an important role in the central effects of ET-1 and ET-1 and ET\(_{A}\) receptors in the PVN may be involved in regulating the CSAR which contributes to the sympathetic excitation.

Previous studies in our lab have shown that NAD(P)H oxidase-derived reactive oxygen species (ROS) especially superoxide anions in the PVN mediate the CSAR and contributes to the effect of Ang II in the PVN on the CSAR in rats [22,23]. The superoxide anions in the PVN mediate the enhanced sympathetic outflow and CSAR in rats with CHF [24] and hypertension [25]. Accumulated evidences indicate that endothelins activate NAD(P)H oxidases and thereby increase superoxide production, resulting in oxidative stress and cardiovascular dysfunction [26–29]. The aims of this study were to investigate the role of ET-1 and ET\(_{A}\) receptors in the PVN in regulating the CSAR and sympathetic activity and the involvement of the superoxide anions in mediating the effects of ET-1 and ET\(_{A}\) in the PVN in rats.

**Materials and Methods**

Experiments were carried out in male Sprague-Dawley rats weighing between 300 and 400 g. The procedures were approved by the Experimental Animal Care and Use Committee of Nanjing Medical University (No. 20110115) and complied with the Guide for the Care and Use of Laboratory Animals (NIH Publication No. 85–23, revised 1996).
General Procedures

The rats were anesthetized with urethane (800 mg/kg, ip) and α-chloralose (40 mg/kg, ip). Adequate depth of anesthesia was assessed by the absence of corneal reflexes and paw withdrawal response to a noxious pinch. Supplemental doses of urethane and α-chloralose were administered as necessary to maintain an adequate depth of anesthesia. The trachea was cannulated for positive-pressure ventilation using a rodent ventilator (51600, Stoelting, USA) with room air. Arterial blood pressure (ABP) was measured with a pressure transducer (MLT0380, ADInstruments, Australia) through a catheter placed into the right carotid artery. Baroreceptor denervation and vagotomy were carried out and identified as previously reported [22]. Body temperature was maintained at 37 ± 1°C with a heating pad.

PVN Microinjection

Rats were placed in a stereotaxic frame (Stoelting, Chicago). The coordinates for PVN were determined according to the Paxinos and Watson rat atlas [30], which is 1.8 mm caudal from bregma, 0.4 mm lateral to the midline, and 7.9 mm ventral to the dorsal surface. The bilateral PVN microinjections were completed within 1 minute and the microinjection volume for each side was 50 nl. At the end of the experiment, 50 nl of Evans blue (2%) was injected into the microinjection site for the later histological verification. Rats with microinjection sites out of the PVN were excluded from data analysis.

Renal Sympathetic Nerve Activity (RSNA) Recordings

Renal sympathetic nerve was isolated through a retroperitoneal incision. The renal nerve was cut distally to eliminate its afferent activity. The nerve was then placed on a pair of silver electrodes and was immersed in mineral oil. The nerve signals were amplified with an AC/DC differential amplifier (Model 3000, A-M System Inc.) with a low-frequency cutoff at 60 Hz and a high-frequency cutoff at 3000 Hz. The amplified and filtered signals were integrated at time constant of 10 ms. After the section of the central end of the renal nerve at the end of each experiment, the background noise was determined and was subtracted from the integrated values of the RSNA. The raw RSNA, integrated RSNA, ABP and mean arterial pressure (MAP) were simultaneously recorded on a PowerLab data acquisition system (8SP, ADInstruments, Australia) and stored on hard disk. The RSNA was expressed as the percent change from the baseline value.

Table 1. Baseline MAP before PVN microinjection and after epicardial application of capsaicin to induce CSAR.

|                  | Before PVN microinjection | After capsaicin |
|------------------|---------------------------|----------------|
| ACSF             | 90.4±2.3                  | 96.0±2.9       |
| ET-1 (0.1 pmol)  | 90.0±3.5                  | 101.9±4.2*     |
| ET-1 (1 pmol)    | 91.2±4.5                  | 110.4±5.1**    |
| ET-1 (10 pmol)   | 90.2±3.0                  | 119.2±2.0**    |

Ten minutes after the PVN microinjection, the CSAR was evaluated by the RSNA and MAP responses to epicardial application of capsaicin. Values are expressed as mean ± SE.

*P < 0.05 vs. the data before PVN microinjection, †P < 0.05 vs. ACSF. n = 6 for each group.

doi:10.1371/journal.pone.0040748.t001

Evaluation of the CSAR

The heart was exposed with a limited left lateral thoracotomy and the pericardium was removed. The CSAR was elicited by application of a piece of filter paper (3×3 mm) containing capsaicin (1.0 nmol in 2.0 μl) to the epicardial surface of anterior wall of the left ventricle [31]. Each piece of paper was removed 1
minute later. The epicardium was rinsed three times with 10 ml of warm normal saline (38°C). The CSAR was evaluated by the responses of the RSNA and MAP to epicardial application of capsaicin.

Measurement of Superoxide Anion Level

The brain of rat was removed from the skull quickly and flash-frozen in liquid nitrogen and stored at −70°C. Coronal section of the brain was made with cryostat microtome (CM1900, Leica LTD), and the PVN area was punched out with a 15-gauge needle. The punched tissue of the PVN was homogenized and then centrifuged. Protein concentrations in the supernatants were measured with the Bradford assay [32].

Lucigenin-derived chemiluminescence is a valid probe for detecting superoxide anions [33–36]. Superoxide anion level was measured with lucigenin-derived chemiluminescence as our previous report [24]. Briefly, the reaction with superoxide anions was started by addition of dark-adapted lucigenin (5 μM) to sample to cause photon emission which was measured with a luminometer (20/20 n, Turner, CA) for ten times. Average values were calculated and expressed as mean light unit (MLU) per minute per milligram of protein, which represented the superoxide anion level. Background chemiluminescence in the buffer that contains lucigenin was measured.

Drugs
Capsaicin, endothelin-1, BQ123 (cyclo-(D-Asp-Pro-D-Val-Leu-D-Trp), tempol, polyethylene glycol-superoxide dismutase (PEG-SOD) were obtained from Sigma Chemical Co. The drugs were dissolved in artificial cerebrospinal fluid (ACSF) except the capsaicin in normal saline. The ACSF contained the following (mM): 10 dextrose, 125 NaCl, 24 NaHCO3, 5 KCl, 2.5 CaCl2, 1.25 MgSO4, 1.25 KH2PO4).

Protocols
Firstly, the effects of PVN microinjection of different doses of ET-1 (0, 0.1, 1 and 10 pmol) on the CSAR, the baseline RSNA and MAP were determined in four groups of rats respectively (n = 6 for each group). Ten minutes after the PVN microinjection, the CSAR was evaluated by the RSNA and MAP responses to
epicardial application of capsaicin. To exclude the possibility that the effects of ET-1 on the CSAR were caused by diffusion to other brain area, the effects of microinjection of ET-1 (10 pmol) into the anterior hypothalamic area which is adjacent to the PVN were determined (n = 3).

Secondly, the effects of the selective ETA receptor antagonist, BQ123, in the PVN on the CSAR, the baseline RSNA and MAP and responses induced by ET-1 were determined. PVN microinjection of ACSF, ET-1 (10 pmol), BQ123 (40 nmol) and ET-1 pretreated with BQ123 were carried out in four groups of rats (n = 6 for each group). Ten minutes after the PVN microinjection, the CSAR was evaluated. The PVN pretreatment with BQ123 was carried out 15 minutes before ET-1.

Thirdly, the effects of tempol and PEG-SOD in the PVN on the enhanced CSAR and RSNA responses as well as pressor response induced by ET-1 were investigated. PVN microinjection of ACSF, tempol (20 nmol) and PEG-SOD (2 units) alone, as well as ET-1 (10 pmol) pretreated with ACSF, tempol, and PEG-SOD were carried out in six groups of rats (n = 6 for each group). The pretreatment was carried out 15 minutes before ET-1. The CSAR was determined 10 minutes after the PVN microinjection.

Lastly, the effects of the PVN microinjection of ACSF, ET-1 (10 pmol), BQ123 (40 nmol), and ET-1 pretreated with BQ123 on the superoxide anion level in the PVN were determined in 4 groups of rats (n = 6 for each group). The pretreatment was administered 15 minutes before ET-1. Ten minutes after PVN microinjection, the rat was decapitated and prepared for measurement of superoxide anion level in the PVN.

Statistics
Comparisons between groups were made by one-way ANOVA followed by the Newman-Keuls test for post hoc analysis. All statistical analyses were done using computer software (SigmaStat, SPSS 10.0). All data were expressed as mean ± SE. P<0.05 was considered statistically significant.

Results
Effects of Different Doses of ET-1
Microinjection of three doses of ET-1 (0.1, 1, 10 pmol) into the PVN induced dose-related increases in CSAR, baseline RSNA and MAP. Compared with control, three doses of ET-1 significantly increased the baseline RSNA and MAP (Fig. 1A),
but only middle and high doses of ET-1 significantly increased the CSAR (Fig. 1B). Baseline MAP before PVN microinjection and after CSAR has been shown in Table 1. However, microinjection of high dose of ET-1 into the anterior hypothalamic area which is adjacent to the PVN failed to cause any significant effect on the CSAR.

Effects of BQ123
The representative recordings showed that PVN microinjection of ET-1 enhanced the CSAR, which was abolished by pretreatment with ETA receptor antagonist BQ123 (Fig. 2). As showing in Figure 3, PVN microinjection of BQ123 alone had no significant effects on the CSAR, RSNA and MAP, but abolished the enhanced CSAR and RSNA responses and pressor response induced by ET-1.

Effects of Tempol and PEG-SOD
Pretreatment with microinjection of superoxide anion scavenger tempol or analogue of endogenous superoxide dismutase PEG-SOD into the PVN inhibited the increasing effects of ET-1 on the CSAR, the baseline RSNA and MAP. Tempol or PEG-SOD alone decreased the CSAR, the baseline RSNA and MAP (Fig. 4).

Superoxide Anion Level in the PVN
Compared with ACSF, microinjection of ET-1 into the PVN significantly increased the superoxide anion level in the PVN, which was abolished by PVN pretreatment with BQ123. BQ123 alone had no significant effect on the superoxide anion level (Fig. 5). Epicardial application of capsaicin to induce CSAR increased superoxide anion level in the PVN. Pretreatment with PVN microinjection of ET-1 enhanced the response of superoxide anion level to epicardial application of capsaicin (Fig. 6).

Discussion
Cardiac sympathetic afferent reflex (CSAR) is known as a positive-feedback, sympathoexcitatory cardiovascular reflex. The cardiac sympathetic afferents are stimulated by endogenous chemicals such as bradykinin, adenosine or hydrogen peroxide released from the myocardium during myocardial ischemia and result in sympathetic activation [10]. Direct electrical stimulation of cardiac sympathetic afferent nerves or epicardial application of exogenous chemicals such as bradykinin or capsaicin can induce CSAR [37]. We have found that paraventricular nucleus (PVN) is an important integrative center in the control of the CSAR [38]. The enhanced CSAR in chronic heart failure [12,39] and hypertension [13] partially contributes to the excessive sympathetic activity that involves in the pathogenesis and the progression of organ damage in these diseases [11,40,41].

It has been reported that the aminopropionic acid receptors in the PVN are involved in mediating the pressor response to ET-1 in SFO [21]. The PVN lesion prevents the intracerebroventricular application of ET-1-induced increase in arterial pressure and AVP secretion, showing the importance of the PVN in the effects of ET-1 in the central nervous system [6]. In the present study, microinjection of ET-1 into the PVN enhanced CSAR, increased baseline RSNA and MAP, which was abolished by the pretreatment with ETA receptor antagonist BQ123 in the PVN. However, BQ123 itself in the PVN had no significant effect on the CSAR, RSNA and MAP. These results suggest that endogenous ET-1 in the PVN enhances the CSAR, RSNA and MAP which is mediated by ETA receptors, but endogenous ET-1 in PVN does not involve in the tonic control of the CSAR and sympathetic activity.

Our previous studies have shown that NAD(P)H oxidase-derived superoxide anions in the PVN mediate the enhanced CSAR and sympathetic outflow and are involved in Ang II-induced CSAR-enhancing effects in the PVN in rats with chronic heart failure rats [24] and hypertension [25]. Long-term administration of tempol attenuates ventricular dysfunction and normalizes sympathetic neural control in myocardial infarction rats [42]. It has been reported that the increased ROS level induced by the activation of ETA receptors in the heart is associated with cardiac hypertrophy in the aryldihydrocarbon receptor null mice [43]. Chronic intravenous ET-1 infusion increases vascular superoxide anions production and plasma thiobarbituric acid-reactive substance (TBARS) level [44]. In the present study, tempol and PEG-SOD were used to scavenge the superoxide anions in the PVN. The PEG-SOD is better in prolonging the circulatory half-life of the native enzymes and enhancing their intracellular access compared with SOD [45]. We found that the PVN microinjection of tempol or PEG-SOD inhibited the excitatory effects of ET-1 on the CSAR, RSNA and MAP. The PVN microinjection of ET-1 increased the superoxide anion level, which was abolished by the pretreatment with ETA receptor antagonist BQ123 in the PVN. Epicardial application of capsaicin to induce CSAR increased superoxide anion level in the PVN which is identical to our previous findings [24,25]. ET-1 in
involved in the tonic generation of superoxide anions in normal suggesting that the endogenous ET-1 in the PVN may be not PVN had no significant effect on the superoxide anion level, suggesting that the endogenous ET-1 in the PVN may be not involved in the tonic generation of superoxide anions in normal rats. It is highly likely that there is some other mechanisms besides ET-1 that may be driving the superoxide anions in PVN with CSAR activation.

In conclusion, exogenous activation of ETA receptors with ET-1 in the PVN enhances the CSAR, increases RSNA and MAP. Superoxide anions in PVN are involved in the effects of ET-1 on the CSAR, RSNA and MAP in rats. However the effects of ET-1 in the PVN in cardiovascular diseases such as hypertension or chronic heart failure remain to be clarified in further experiments.

Author Contributions
Conceived and designed the experiments: ADC YH. Performed the experiments: ADC YH. Analyzed the data: ADC FZ YXG YH. Wrote the paper: ADC YH.

References
1. Rossi NF, O’Leary DS, Woodbury D, Chen H (2000) Endothelin-1 in hypertension in the baroreflex-intact SHR: a role independent from vasopressin release. Am J Physiol Endocrinol Metab 279: E18-E24.
2. Burnier M, Forni V (2012) Endothelin receptor antagonists: a place in the management of essential hypertension? Nephrol Dial Transplant 27: 865-868.
3. Kowakai T, Gao WH, Kumada M (1994) Endothelin in the brain and its effect on cardiovascular control of the circulation and other functions. Jpn J Physiol 44: 1-10.
4. Nishimura M, Takahashi H, Matsuoka I, Isegaki I, Sakamoto M, et al. (1991). Chronic intracerebroventricular infusions of endothelin elevate arterial pressure in rats. J Hypertension 9: 71-76.
5. Gulati A, Rebello S, Kumar A (1997) Role of sympathetic nervous system in cardiovascular effects of centrally administered endothelin-1 in rats. Am J Physiol 273: H1177-H1186.

ET-1-induced increases in systemic arterial pressure and vasopressin. Am J Physiol Endocrinol Metab 280: E349-E356.
7. Nakamura K, Satoh S, Morishita S, Miki S, et al. (1999) Central effects of endothelin and its antagonists on sympathetic and cardiovascular regulation in SHR-SF. J Cardiovasc Pharmacol 33: 876-882.
8. Yamamoto T, Kunura T, Oka K, Shoji M, Inoue M, et al. (1991) Central effects of endothelin-1 on vasopressin and atrial natriuretic peptide release and cardiovascular and renal function in conscious rats. J Cardiovasc Pharmacol 17 Suppl 7: S316-S318.

9. Rossi NF, O’Leary DS, Chen H (2001) PVN lesions prevent the endothelin-1-induced increase in arterial pressure and vasopressin. Am J Physiol Endocrinol Metab 280: E349-E356.
10. Malfani A, Montano N (2002) Emerging excitatory role of cardiovascular sympathetic afferents in pathophysiological conditions. Hypertension 39: 63-68.
11. Zucker IH, Piquette RU (2002) Novel mechanisms of sympatho-excitation in chronic heart failure. Heart Fail Monit 8: 1-7.
12. Gan XB, Duan YC, Xiong XQ, Li P, Cui BP, et al. (2011) Inhibition of Cardiac Sympathetic Afferent Reflex and Sympathetic Activity by Baroreceptor and Vagal Afferent Inputs in Chronic Heart Failure. PLoS ONE 6: e27509.
13. Zhu GQ, Xu Y, Zhou LM, Li YH, Fan LM, et al. (2009) Enhanced cardiac sympathetic afferent reflex involved in sympathetic overactivity in renovascular hypertensive rats. Exp Physiol 94: 765.
14. Han Y, Yuan N, Zhang SJ, Gao J, Shi Z, et al. (2011) e-Sec in paraventricular nucleus modulates sympathetic activity and cardiac sympathetic afferent reflex in renovascular hypertensive rats. Pflugers Arch 461: 437-446.
15. Zhou MK, Duan VC, Chen AD, Xu B, Gao XY, et al. (2008) Paraventricular Nucleus Is Involved in the Central Pathway of Cardiac Sympathetic Afferent Reflex in Rats. Exp Physiol 93: 746-753.
16. Zahner MR, Pan HL (2005) Role of paraventricular nucleus in the cardiac sympathetic reflex in rats. Am J Physiol Regul Integr Comp Physiol 288: R420–R426.
17. Horwitz MJ, Bloch KD, Kim NB, Amico JA (1994) Expression of the endothelin-1 and oxytocin genes in the hypothalamus of the pregnant rat. Brain Res 648: 59-64.
18. He JJ, Chen XQ, Wang L, Xu JF, Du JZ (2000) Cotrimoxazole-releasing hormone receptor 1 cocultured with endothelin-1 and modulates its mRNA expression and release in rat paraventricular nucleus during hypoxia. Neuroscience 112: 1006-1014.
19. Jones CR, Hiley CR, Pelton JT, Molder M (1989) Autoradiographic visualization of the binding sites for [125I]endothelin in rat and human brain. Neurosci Lett 97: 276-279.
20. Fuxe K, Anggard E, Lundgren K, Cintra A, Agnati LF, et al. (1989) Localization of [125I]endothelin-1 and [125I]endothelin-3 binding sites in the rat brain. Acta Neurobiol Exp 49: 537-564.
21. Rossi NF, Chen H (2006) Aminopropionic acid receptors in paraventricular nucleus mediate pressor and vasopressin responses to endothelin-1 in subformical organ. Exp Biol Med (Maywood) 231: 1075-1080.
22. Han Y, Zhang Y, Wang HJ, Gao XY, Wang W, et al. (2005) Reactive oxygen species in paraventricular nucleus modulates cardiac sympathetic afferent reflex in rats. Brain Res 1056: 82-90.
23. Zhang Y, Yu Y, Zhang F, Zhou MK, Shi Z, et al. (2006) NAD(P)H oxidase in paraventricular nucleus contributes to the effect of angiotensin II on cardiac sympathetic afferent reflex. Brain Res 1082: 132-141.
24. Han Y, Shi Z, Zhang F, Yu Y, Zhou MK, et al. (2007) Reactive oxygen species in the paraventricular nucleus mediate the cardiac sympathetic afferent reflex in chronic heart failure rats. Eur J Heart Fail 9: 967-973.
25. Han Y, Fan ZD, Yuan N, Xie GQ, Gao J, et al. (2011) Superoxide anions in paraventricular nucleus mediate the enhanced cardiac sympathetic afferent reflex and sympathetic activity in renovascular hypertensive rats. J Appl Physiol 110: 646-652.
26. Dammannahalli KJ, Sun Z (2008) Endothelins and NADPH oxidases in the cardiovascular system. Clin Exp Pharmacol Physiol 35: 2–6.
27. Just A, Whittem CL, Arrendahour WV (2008) Reactive oxygen species participate in acute renal vasoconstrictor responses induced by ETA and ETB receptors. Am J Physiol Renal Physiol 294: F179-F278.
28. Zeng Q, Zhou Q, Yao F, O’Rourke ST, Sun C (2006) Endothelin-1 regulates cardiac L-type calcium channels via NADPH oxidase-derived superoxide. J Pharmacol Exp Ther 326: 732-738.
29. De Giusti V, Correa MV, Villa-Abreu MC, Beltrano C, Veves AM, et al. (2008) The positive inotropic effect of endothelin-1 is mediated by mitochondrial reactive oxygen species. Life Sci 83: 264-271.
30. Paxinos G, Watson C (2005) The rat brain in stereotaxic coordinates, 5th Edition ed. San Diego, CA: Elsevier Academic Press.
31. Zhu GQ, Xu Y, Zhou LM, Li YH, Fan LM, et al. (2009) Enhanced cardiac sympathetic afferent reflex involved in sympathetic overactivity in renovascular hypertensive rats. Exp Physiol 94: 785-794.
32. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254.
33. Gao L, Wang W, Li YI, Schulz HD, Liu D, et al. (2004) Superoxide mediates sympathoexcitation in heart failure: roles of angiotensin II and NAD(P)H oxidase. Circ Res 95: 937-944.
34. Li Y, Zhu H, Kuppusamy P, Roubaut V, Zweier JL, et al. (1998) Validation of lucigenin [bis(N-methylacridinium)] as a chemiluminescent probe for detecting superoxide anion radical production by enzymatic and cellular systems. J Biol Chem 273: 2015–2023.
35. Tai MH, Wang WL, Wu KL, Chan JY (2005) Increased superoxide anion in rostral ventromedial medulla contributes to hypertension in spontaneously hypertensive rats via interactions with nitric oxide. Free Radic Biol Med 38: 450–462.
36. Meimaridou E, Jacobson J, Seddon AM, Noronha-Dutra AA, Robertson WG, et al. (2005) Crystalline and microparticle effects on MDCK cell superoxide production: oxalate-specific mitochondrial membrane potential changes. Free Radic Biol Med 38: 1555–1564.
37. Du YH, Chen AF (2007) A "love triangle" elicited by electrochemistry: complex interactions among cardiac sympathetic afferent, chemo-, and baroreflexes. J Appl Physiol 102: 9–10.
38. Zhou MK, Duan YC, Chen AD, Xu B, Gao XY, et al. (2008) Paraventricular Nucleus Is Involved in the Central Pathway of Cardiac Sympathetic Afferent Reflex in Rats. Exp Physiol 93: 746-753.
39. Wang W, Ma R (2008) Cardiac sympathetic afferent reflexes in heart failure. Heart Fail Rev 5: 57-71.
40. Mancia G, Grassi G, Giannattasio C, Servaalle G (1999) Sympathetic activation in the pathogenesis of hypertension and progression of organ damage. Hypertension 34: 724-729.
41. Gu R, Lu W, Xie J, Bai J, Xu B (2011) Renalase deficiency in heart failure model of rats: a potential mechanism underlying circulating norepinephrine accumulation. PLoS One 6: e14633.
42. Shi Z, Chen AD, Xu Y, Chen Q, Gao XY, et al. (2009) Long-term administration of tempol attenuates postinfarct ventricular dysfunction and sympathetic activity in rats. Pflugers Arch 458: 247–257.

43. Lund AK, Peterson SL, Timmins GS, Walker MK (2005) Endothelin-1-mediated increase in reactive oxygen species and NADPH Oxidase activity in hearts of aryl hydrocarbon receptor (AhR) null mice. Toxicol Sci 88: 265–273.

44. Yao L, Kobori H, Rahman M, Seth DM, Shokoji T, et al. (2004) Olmesartan improves endothelin-induced hypertension and oxidative stress in rats. Hypertens Res 27: 493–500.

45. Liu TH, Beckman JS, Freeman BA, Hogan EL, Hsu CY (1989) Polyethylene glycol-conjugated superoxide dismutase and catalase reduce ischemic brain injury. Am J Physiol 256: H589–H593.